Low-dose growth hormone therapy reduces inflammation in HIV-infected patients: a randomized placebo-controlled study

Johanne Bjerre Lindboe, Anne Langkilde, Jesper Eugen-Olsen, Birgitte R Hansen, Thomas H Haupt, Janne Petersen, Ove Andersen

8 Citationer (Scopus)

Abstrakt

BACKGROUND: Combination antiretroviral therapy (cART) has drastically increased the life expectancy of HIV-infected patients. However, HIV-infected patients exhibit increased inflammation and 33-58% exhibit a characteristic fat re-distribution termed HIV-associated lipodystrophy syndrome (HALS). Recombinant human growth hormone (rhGH) has been tested as treatment of HALS. Low-dose rhGH therapy improves thymopoiesis and fat distribution in HIV-infected patients and appears to be well tolerated. However, since high-dose rhGH is associated with adverse events related to inflammation, we wanted to investigate the impact of low-dose rhGH therapy on inflammation in HIV-infected patients.

METHODS: Forty-six cART-treated HIV-infected men were included in the HIV-GH low-dose (HIGH/Low) study: a randomized, placebo-controlled, double-blinded trial. Subjects were randomized 3:2 to 0.7 mg/day rhGH, or placebo for 40 weeks. rhGH was self-administered between 1 pm and 3 pm. The primary outcome of this substudy was changes in inflammation measured by plasma C-reactive protein (CRP) and soluble urokinase plasminogen activator receptor (suPAR).

RESULTS: Both CRP (-66%, p = 0.002) and suPAR (-9.7%, p = 0.06) decreased in the rhGH group compared to placebo; however, only CRP decreased significantly. The effect of rhGH on inflammation was not mediated through rhGH-induced changes in insulin-like growth factor 1, body composition, or immune parameters.

CONCLUSION: Daily 0.7 mg rhGH treatment for 40 weeks, administered at nadir endogenous GH secretion, significantly reduced CRP. The effect does not appear to be mediated by other factors. Our findings suggest that low-dose rhGH treatment may minimize long-term risks associated with high-dose rhGH therapy.

OriginalsprogEngelsk
TidsskriftInfectious diseases (London, England)
Vol/bind48
Udgave nummer11-12
Sider (fra-til)829-837
DOI
StatusUdgivet - dec. 2016

Fingeraftryk

Dyk ned i forskningsemnerne om 'Low-dose growth hormone therapy reduces inflammation in HIV-infected patients: a randomized placebo-controlled study'. Sammen danner de et unikt fingeraftryk.

Citationsformater